Tulasee Rao Chintha
InpharmD | YC W21
A real AI Specialist (wrote ~10k lines of AI code) | Raised $8.05 millions | AI Patent Holder | LLM's Expert Built 40 Billion parameters LLM
My Journey
👨🌾 Farmer to Pharma CTO
My journey began in a tiny sweet green little village in Southern India, aiming to farm. But life steered me towards engineering, and eventually, I became the CTO at InpharmD. Grateful for this unexpected path that led me to where I am today.
My journey spans tech roles in India and Corporate America, leading to co-founding InpharmD.
Built an AI-driven platform that transforms healthcare information management, offering precise responses to healthcare professionals. With evidence-based insights, we're making waves in the sector by fostering innovation and driving efficiency like never before, providing them with succinct summaries of literature.
💰Humble beginnings from zeros to billions
In 2018, I co-founded InpharmD. With seed funding of $8.05M, we quickly reached series A, boasting a revenue between $4-8M. We now have a vibrant community of over 50k users, including 10k active daily users.
👨💼 Investor onboard
Our recent funding round was backed by some of the most prestigious investors - 645 Ventures, Atlanta Ventures, Y Combinator, & Qlarant Capital
👨💼 InpharmD CTO
As CTO and Co-founder of InpharmD, I drive technology development, harnessing AI for enhanced patient care and healthcare provider support. I lead web and AI initiatives, processing 30M medical papers, shaping industry advancements.
My focus spans technical strategy, team leadership, and product delivery, ensuring top-notch solutions. Committed to healthcare and AI evolution, I aim to sustain impactful innovation. Enthusiastic about our team and InpharmD's vision, I'm eager to propel positive change in healthcare through cutting-edge approaches.
InpharmD answers complex questions about drugs by using a combination of generative AI and a clinical pharmacist. Clinicians can ask questions about whether a drug is right to give a patient, dosage and side effect questions, and what to do if a drug is not on hand. Hospital committees (P&T) that decide which drugs to use can generate reports on cost-effectiveness of drugs.
“My co-founder Tulasee led the way in AI advancements, helping us transcribe PDFs faster than our pharmacists, though still refining accuracy. With 5,000 study abstracts as our foundation, we've fine-tuned algorithms to match our abstracts. Testing at 94% against humans, we aim for 100% accuracy in medical data reliability. Introducing Sherlock, our answer to missed opportunities like Watson. Partnering with ASHP, we're integrating 1,300 vetted drug monographs, enabling Sherlock to provide precise answers at the point of care. Excited to revolutionize healthcare decisions with seamless AI integration”
Stay busy building tools for users. Don't be a boilerplate programmer. Instead, build tools for users and other programmers. Take historical note of textile and steel industries: do you want to build machines and tools, or do you want to operate those machines.
— Ras Bodik at the start of his compilers course
The top of one mountain is always the bottom of another.
— Marianne Williamson
